

Workplace bullying and psychotropic drug use: the mediating role of physical and mental health status

Isabelle Niedhammer^{1 2 3*}, Simone David¹, Stéphanie Degioanni¹, Anne Drummond², Pierre Philip³

¹ CESP, Centre de recherche en épidémiologie et santé des populations INSERM : U1018, Université Paris XI - Paris Sud, Université de Versailles Saint-Quentin-en-Yvelines, INED, FR

² UCD School of Public Health & Population Science University College Dublin, Dublin, IE

³ Clinique du sommeil CHU Bordeaux, Groupe hospitalier Pellegrin, FR

* Correspondence should be addressed to: Isabelle Niedhammer <isabelle.niedhammer@inserm.fr >

Drs ACQUARONE D, AICARDI F, ANDRE-MAZEAUD P, ARSENTO M, ASTIER R, BAILLE H, BAJON-THERY F, BARRE E, BASIRE C, BATTU JL, BAUDRY S, BEATINI C, BEAUD'HUIN N, BECKER C, BELLEZZA D, BEQUE C, BERNSTEIN O, BEYSSIER C, BLANC-CASCIO F, BLANCHET N, BLONDEL C, BOISSELOT R, BORDES-DUPUY G, BORRELLY N, BOUHNIC D, BOULANGER MF, BOULARD J, BOURREAU P, BOURRET D, BOUSTIERE AM, BRETON C, BUGEON G, BUONO-MICHEL M, CANONNE JF, CAPELLA D, CAVIN-REY M, CERVONI C, CHARRETON D, CHARRIER D, CHAUVIN MA, CHAZAL B, COUGNOT C, CUVELIER G, DALIVOUST G, DAUMAS R, DEBAILLE A, DE BRETTEVILLE L, DELAFORGE G, DELCHAMBRE A, DOMENY L, DONATI Y, DUCORD-CHAPELET J, DURAN C, DURAND-BRUGUEROLLE D, FABRE D, FAIVRE A, FALLERI R, FERRANDO G, FERRARI-GALANO J, FLUTET M, FOCHE JP, FOURNIER F, FREYDER E, GALY M, GARCIA A, GAZAZIAN G, GERARD C, GIRARD F, GIUGE M, GOYER C, GRAVIER C, GUYOMARD A, HACQUIN MC, HALIMI E, IBAGNES T, ICART P, JACQUIN MC, JAUBERT B, JORET JP, JULIEN JP, KACEL M, KESMEDJIAN E, LACROIX P, LAFON-BORELLI M, LALLAI S, LAUDICINA J, LECLERCQ X, LEDIEU S, LEROY J, LEROYER L, LOESCHE F, LONDI D, LONGUEVILLE JM, LOTTE MC, LOUVAIN S, LOZE M, MACULET-SIMON M, MAGALLON G, MARCELOT V, MAREEL MC, MARTIN P, MASSE AM, MERIC M, MILLIET C, MOKHTARI R, MONVILLE AM, MULLER B, OBADIA G, PELSER M, PERES L, PEREZ E, PEYRON M, PEYRONNIN F, POSTEL S, PRESSEQ P, PYRONNET E, QUINSAT C, RAULOT-LAPOINTE H, RIGAUD P, ROBERT F, ROBERT O, ROGER K, ROUSSEL A, ROUX JP, RUBINI-REMIGY D, SABATE N, SACCOMANO-PERTUS C, SALENGRO B, SALENGRO-TRUILLEZ P, SAMSOM E, SENDRA-GILLE L, SEYRIG C, STOLL G, TARPINIAN N, TAVERNIER M, TEMPESTA S, TERRACOL H, TORRESANI F, TRIGLIA MF, VANDOMME V, VIEILLARD F, VILMOT K, VITAL N

Abstract

Objectives

The association between workplace bullying and psychotropic drug use is not well established. This study was aimed at exploring the association between workplace bullying, and its characteristics, and psychotropic drug use, and studying the mediating role of physical and mental health.

Methods

The study population consisted of a random sample of 3132 men and 4562 women of the working population in the South-East of France. Workplace bullying, evaluated using the validated instrument elaborated by Leymann, and psychotropic drug use, as well as covariates, were measured using a self-administered questionnaire. Covariates included age, marital status, presence of children, education, occupation, working hours, night work, physico-chemical exposures at work, self-reported health, and depressive symptoms. Statistical analysis was performed using logistic regression analysis, and was carried out separately for men and women.

Results

Workplace bullying was strongly associated with psychotropic drug use. Past exposure to bullying increased the risk for this use. The more frequent and the longer the exposure to bullying, the stronger the association with psychotropic drug use. Observing bullying on someone else at the workplace was associated with psychotropic drug use. Adjustment for covariates did not modify the results. Additional adjustment for self-reported health and depressive symptoms reduced the magnitude of the associations, especially for men.

Conclusion

The association between bullying and psychotropic drug use was found to be significant and strong, and was partially mediated by physical and mental health.

Author Keywords psychotropic drug use ; workplace bullying ; mental health ; self-reported health

INTRODUCTION

The use of psychotropic drugs, aimed at bringing a symptomatic response to mental disorders, has increased within the last few decades in industrialised countries, and this category of drugs is now amongst the most commonly prescribed. The ESEMeD project showed that 8% of males and 16% of females took at least one psychotropic drug in the past 12 months in Europe (Alonso et al., 2004). In France, 24% of the population (17% of men, 31% of women) were reimbursed for a psychotropic medication during the year 2000 (Lecadet et al., 2003) and psychotropic drug use may be higher than in other European countries (Alonso et al., 2004). A variety of factors

may explain the differences between countries, such as access and utilization of health and mental health services, legal rules for prescription, retail and use of psychotropic drugs, but also actual differences in the prevalence of mental disorders. Anxiolytics are currently the most commonly prescribed drugs, antidepressants and hypnotics being less frequently used. This pattern is found in Europe in general (Alonso et al., 2004) and in France in particular (Lecadet et al., 2003). Under-treatment was found to be a common phenomenon: a substantial proportion of subjects with mental disorders did not use psychotropic drugs or were inappropriately treated (Alonso et al., 2004). Although benefits are associated with the use of these drugs, concern has also increased regarding their health effects (side effects), especially with long-term use, and the dependence related to use. Psychotropic drug use may be associated with health, social, and economic consequences, such as cardiac side effects (Witchel et al., 2003), falls in older age (Leipzig et al., 1999), and accidents (Wadsworth et al., 2005). Consequently, psychotropic drug use may be a serious public health issue, because of the high prevalence of use, and their consequences, and a better understanding of the factors associated with use may be useful for preventive action.

The causes of psychotropic drug use are complex and certainly multifactorial. Studies reported that psychotropic drug use was associated with female gender, older age, low socioeconomic status, or living alone (Alonso et al., 2004 ;Lavigne and Bourbonnais, 2010 ; Lecadet et al., 2003). To date, occupational factors have been understudied in relation to psychotropic drug use.

Indeed, little research has been undertaken that targets psychotropic drug use in the working population. Although job stress is suspected to be one of the major occupational risk factors for mental health outcomes, the impact of job stress on psychotropic drug use has not been widely studied. Some studies have shown that measures of job stress, such as high psychological demands, low decision latitude, job strain, low social support, iso-strain, low reward, or effort-reward imbalance were associated with psychotropic drug use (Lavigne and Bourbonnais, 2010 ;Moisan et al., 1999 ;Pelfrene et al., 2004 ;Virtanen et al., 2007). However, these studies were done on relatively small or selective samples, and/or did not take adequate account of potential confounding factors such as socio-demographic factors, physical and mental health status, or important occupational risk factors such as night work and working hours. Furthermore, a still lower number of studies have explored the association between workplace bullying, considered to be one of the most damaging job stress factors, and psychotropic drug use, and the literature in this area appears still more sparse (Appelberg et al., 1993 ;Lavigne and Bourbonnais, 2010 ;Richman et al., 1999 ;Vartia, 2001 ;Traweger et al., 2004).

Workplace bullying is difficult to evaluate, and no consensus exists regarding its definition. Here, the definition by Leymann (Leymann, 1996b) was adopted: workplace bullying 'involves hostile and unethical communication, which is directed in a systematic way by one or a few individuals mainly towards one individual who is pushed into a helpless and defenceless position'. Two approaches using self-reported questionnaires have been developed in surveys: inventories of various forms of bullying, and self-report of being exposed to bullying on the basis of a given definition. According to some authors, the combination of both approaches would be adequate to define cases of bullying (Einarsen and Skogstad, 1996 ;Einarsen, 2000 ;Vartia, 1996 ;Vartia, 2001). Duration and frequency of bullying would also be crucial elements. In the present study, we used the questionnaire elaborated by Leymann, the Leymann Inventory of Psychological Terror (LIPT) (Leymann, 1996a), considered to have the greatest coverage and acceptable reliabilities (Cowie et al., 2002), and also the second approach based on self-report of being exposed to bullying.

The objectives of this study were to examine the associations between workplace bullying and psychotropic drug use. This study attempted to take the previous limitations described earlier into account, as it was based on a large and non-selective sample of the working population, it included a standard measure of exposure to workplace bullying, and detailed information on this exposure, took account of a large number of confounding factors, and studied the specific mediating role of physical and mental health in the association between workplace bullying and psychotropic drug use.

METHODS

Population

This cross-sectional survey was performed by INSERM in 2004 among the general working population in the southeast of France in collaboration with a network of 143 voluntary occupational physicians, who, if working full-time, selected 150 employees each randomly, and invited them to participate in the survey. Occupational medicine is mandatory for all employees in France, consequently, every employee has a medical examination with an occupational physician periodically; at the time of the survey, this was annually. In order to be included in the survey, employees had to have worked for at least 3 months in their company. The survey was based on a self-administered questionnaire which was anonymous, and was returned using a prepaid envelope. Because employees included in the survey were all working at the time of the survey, it could be assumed that those who had a major mental health disorder might be underrepresented in the sample because these people would be more likely to be on sick leave. Several papers have already been published on the topic of workplace bullying using this study sample (Niedhammer et al., 2006b ;Niedhammer et al., 2006a ;Niedhammer et al., 2007 ;Niedhammer et al., 2009).

Variables

Our questionnaire included a French version of the LIPT, measuring the experience of 45 forms of bullying within the previous 12 months, as well as frequency and duration of bullying. The reference period for exposure was 12 months making it possible to study exposure to bullying even in a previous job (inclusion criterion in the survey was at least 3 months in the company, consequently exposure to bullying in a previous job was also explored). Afterwards, the employees were given the following definition: 'Bullying may be defined by a situation in which someone is exposed to hostile behaviours on the part of one or more persons in the work environment which aim continually and repeatedly to offend, oppress, maltreat, or to exclude or isolate over a long period of time.' The employees were asked if they perceived themselves as being exposed to bullying within the past 12 months. Cases of bullying were defined using both Leymann's definition (exposure to at least one form of bullying within the previous 12 months, weekly or more, and for at least 6 months) (Leymann, 1996b) and the self-report of being exposed to bullying, as recommended previously (Einarsen and Skogstad, 1996; Einarsen, 2000; Vartia, 1996; Vartia, 2001). The psychometric properties of the French version of the LIPT questionnaire were studied in a previous paper (Niedhammer et al., 2006a), and we found that the combined evaluation of bullying increased the convergent and predictive validity compared with Leymann's definition alone. Several other variables were used to characterize the exposure to workplace bullying within the 12 past months, which were the period of exposure (current or past), and the frequency and duration of exposure. In addition, we used a variable describing the fact that the employees may have been observers of bullying experienced by someone else at their workplace within the 12 past months. We also constructed a variable combining the two variables of exposure to bullying and observing bullying by creating four categories: no exposure at all, observer of bullying, exposure to bullying, and both exposure to bullying and observer of bullying.

Psychotropic drug use was measured using one question evaluating whether a medication to sleep, a tranquilizer, or another psychotropic drug for mental disorders had been taken within the previous 12 months. This variable was used as a marker of sleep and mental health disorders. Drug abuse and recreational use of these drugs were not the focus of the study.

Several variables were used as covariates because they are considered as known or suspected risk factors of psychotropic drug use in the literature and may play a confounding role in the association between bullying and psychotropic drug use: age, marital status, presence of children, educational level, occupational groups (derived from the French classification of occupations -INSEE- that is close to the International Standard Classification of Occupations -ISCO- and included: blue collar workers, clerks/service workers, associate professionals, managers/professionals), working hours per week, night work (permanent night work or alternating shifts including night shift), and the number of physico-chemical exposures at work to thermic constraints (outdoor work, cold or hot temperatures), noise, radiation, chemical exposures, or other exposures. Two health-related variables were also studied: poor self-reported health, based on a 4-level scale ranging from 'very good' (coded 1) to 'very poor' (coded 4), and defined by levels 3 and 4, and depressive symptoms measured using the CES-D scale and defined using the available thresholds established for the French population (≥ 17 for men and ≥ 23 for women) to dichotomize the CES-D score (Fuhrer and Rouillon, 1989). Age, marital status, and educational level are well-known risk factors of psychotropic drug use (Alonso et al., 2004; Lavigne and Bourbonnais, 2010; Lecadet et al., 2003; Moisan et al., 1999; Pelfrene et al., 2004). As our variable of interest was workplace bullying, a careful consideration was also given to potential occupational risk factors of psychotropic drug use, occupational group, working hours, night work, and physico-chemical exposures, that may increase the risk of psychotropic drug use (Niedhammer et al., 1995; Pelfrene et al., 2004). Finally, self-reported health and depressive symptoms were studied as markers of physical and mental health status, in order to explore their potential mediating role in explaining the association between bullying and psychotropic drug use, something never done before.

Statistical analysis

The crude associations between 6 variables characterizing bullying, i.e. exposure, period, frequency, duration of bullying and the two variables of observing bullying, covariates, and psychotropic drug use were studied using Pearson's Chi-Square test. Logistic regression analysis was then used to adjust for covariates (except self-reported health and depressive symptoms). Six different models were constructed with psychotropic drug use as the dependent variable. In each model, we included as independent variables simultaneously: one of the 6 variables describing bullying, as well as the covariates (model 1). Additional models were also performed with additional adjustment for poor self-reported health and depressive symptoms, that were added in the previous models as covariates (model 2). The mediating role of these two health-related variables was estimated by the change in odds ratio (OR) according to the formula: $(OR_{\text{model 1}} - OR_{\text{model 2}}) / (OR_{\text{model 1}} - 1)$ (Lynch et al., 1996). The OR, or the prevalence-odds ratio as the study design is here cross-sectional, is the ratio of the odds in favour of disease among the exposed to the odds in favour of disease among the unexposed. As differences may be observed between men and women for the prevalences of occupational exposures (including bullying), and of health outcomes (including psychotropic drug use), and as the associations between exposures and outcomes may also differ between genders, analysis was carried out separately for men and women (Niedhammer et al., 2000). Statistical analysis was performed using SAS.

RESULTS

In 2004, 19655 employees were asked to participate in the survey. Among them, 7770 responded to the self-administered questionnaire, leading to a response rate of 40%. Seventy six employees were excluded from the analysis, 57 because they had worked for

less than 3 months in their company, and 19 because sex response was missing in the questionnaire. Thus, the study was based on 7694 employees, 3132 men and 4562 women, with a mean age of 40 (standard deviation: 10.3). The 12-month prevalence of psychotropic drug use was 19% and 33% for men and women respectively.

Leymann's definition alone led to a 12-month prevalence of exposure to bullying of 11% for men and 13% for women. Using the definition of exposure to bullying combining Leymann's definition and the self-reporting of bullying by the employees within the same period, the 12-month prevalence of exposure to bullying were respectively 9% and 11% for men and women. These results show that most of those defined as exposed to bullying using Leymann's definition also reported being exposed.

All the associations between the variables of bullying and psychotropic drug use were strongly significant at $p < 0.001$ (Table 1). The prevalence of psychotropic drug use increased among people exposed to workplace bullying, especially among those who were currently exposed. People who were exposed to bullying in the past were also at higher risk of psychotropic drug use than those who had never been exposed. Significant associations were observed between the frequency and duration of exposure to bullying and psychotropic drug use. Observing bullying was also associated with an increase in the prevalence of psychotropic drug use. The highest prevalence of psychotropic drug use was observed for those exposed to bullying (with or without observing it) for both genders.

The prevalence of psychotropic drug use increased with age, among those living alone, among women having no children, among those having a lower educational level, among male clerks or service workers, among night workers, and among women exposed to physico-chemical exposures at work. The prevalence of psychotropic drug use also increased strongly with poor self-reported health and depressive symptoms (Table 2).

Table 3 provides the results of logistic regression analysis (model 1). Each model shows the association between each variable of bullying and psychotropic drug use after adjustment for covariates. All these associations were strongly significant at $p < 0.001$, suggesting that covariates did not modify the strong associations observed in Table 1 . Exposure to workplace bullying within the last 12 months was found to be a strong risk factor for psychotropic drug use. Past exposure to bullying also increased this risk. The more frequent and the longer the exposure to bullying, the higher the prevalence of use. Tests for trend of frequency and duration of bullying showed dose-response associations significant at $p < 0.0001$. Observing bullying of someone else increased the risk of psychotropic drug use. Exposure to bullying with or without observing bullying at the workplace led to the highest increases in the risk of psychotropic drug use.

These results from logistic regression analysis (Table 3) also showed that older age and living alone for both genders, occupation and night work for men only, and physico-chemical exposures for women only were found to be significant independent risk factors for psychotropic drug use (Table 4).

Additional adjustment for self-reported health and depressive symptoms (model 2) led to a substantial reduction in the magnitude of the ORs, and the associations between bullying and psychotropic drug use remained significant at $p < 0.001$ in women (Table 5). Inclusion of self-reported health and depressive symptoms in the models led to a reduction of the ORs for those exposed to bullying from 3.10 to 1.31 for men and from 3.49 to 1.78 for women, i.e. a reduction of 85% and 69% respectively.

DISCUSSION

Main findings

This study shows that workplace bullying was strongly associated with psychotropic drug use. Dose-response associations were observed between frequency and duration of bullying and psychotropic drug use. Observing bullying of someone else at the workplace was a risk factor of psychotropic drug use. All these associations were independent of potential confounding factors. However, taking physical and mental health into account reduced the magnitude of the associations between bullying and psychotropic drug use, suggesting a mediating role of these health-related variables.

Strengths and limitations of the study

Some limitations of the study deserve to be mentioned. The response rate may be considered as low (40%), but it is similar to previous studies on this sensitive topic (Bjorkqvist et al., 1994 ;Einarsen et al., 1994 ;Hoel et al., 2001 ;Salin, 2001). Selection bias may not be ruled out, but the differences between respondents and non-respondents were small for sex, age, economic activities, and occupation. In addition, a comparison between the census population and the sample studied suggested that the study population was roughly representative for the same variables (Niedhammer et al., 2006a). A specific type of healthy worker effect (leading to exclude people in poor health from the labour market) may have operated, as this survey did not include employees on sickness absence within the survey period, especially those who were on sick leave because of the health consequences of workplace bullying, leading to a potential underestimation of the association between bullying and psychotropic drug use. The cross-sectional design of our study did not allow us to conclude on the causal nature of the association between workplace bullying and psychotropic drug use, and a reverse causation may not be excluded. A reporting bias may also be suspected as both workplace bullying and psychotropic drug use were measured using

self-report. This reporting bias, which is connected to 'common method variance', for example through negative affectivity and social desirability, may lead to inflated associations between the two variables. Another limitation is related to the use of a rather crude measure for psychotropic drug use. Although other authors used a similar measure (Lavigne and Bourbonnais, 2010), this did not allow us to study the specific classes of psychotropics, the reason or duration for medication.

The strengths of this study were the following. Our sample included a very large number of employees of the general working population, allowing us to study a nonselective population as well as men and women separately, which has been shown to be crucial (Niedhammer et al., 2000). Another type of healthy worker effect (people in poor health shifted to less exposed jobs) was taken into account as we were able to study exposure to bullying in a previous job. A validated instrument was used to measure workplace bullying (LIPT), and various variables were constructed to describe the exposure to workplace bullying which has never been done before in the study of psychotropic drug use, and provided detailed information on exposure to bullying and its associations with psychotropic drug use. The prevalence of psychotropic drug use observed for men and women in our study (19–33%) was consistent with previous results in the French population (17–31%) (Lecadet et al., 2003), and strong and consistent associations were also found with classical risk factors such as gender, age, and marital status, in accordance with previous studies (Alonso et al., 2004; Lavigne and Bourbonnais, 2010; Lecadet et al., 2003; Moisan et al., 1999; Pelfrene et al., 2004). Regarding occupational factors, we found that occupation was significantly associated with psychotropic drug use among men (blue collar workers being at lower risk, and white collar workers at higher risk), in agreement with the results by Pelfrene et al. (Pelfrene et al., 2004). We observed an association between night work and psychotropic drug use as reported previously (Niedhammer et al., 1995). An association was also found between physico-chemical exposures at work and psychotropic drug use, that may suggest that other occupational exposures may be risk factors. Finally, as expected, strong and significant associations were found between self-reported health and depressive symptoms, and psychotropic drug use. All these results reinforce the validity of our study. The statistical analysis took into account important covariates in the study of the association between workplace bullying and psychotropic drug use; sociodemographic and occupational factors, as well as health-related factors. Although a substantial number of covariates were taken into account, some variables may have been omitted because they were unavailable in the survey, such as smoking or alcohol consumption. Psychosocial work factors, such as social support, were not taken into account because it is likely that these variables may be risk factors of bullying, and would lead to overadjustment in the analysis. We demonstrated in a previous paper that occupation was associated with bullying, especially that male managers/professionals were less likely to be exposed to bullying (Niedhammer et al., 2007). Our results that were adjusted for occupation (among others) suggested that bullying was associated with psychotropic drug use independently of occupational groups. However, as occupational group may be a risk factor of bullying, adjusting for occupation may also be considered as an overadjustment in the study of the association between bullying and psychotropic drug use. As the association was very strong, adjusting was preferred even if it may be viewed as a conservative strategy. Whereas sociodemographic and occupational covariates did not modify the strong associations between bullying and psychotropic drug use, health-related covariates reduced these associations, suggesting a mediating role of these covariates.

Comparison with literature

Only very few studies examined the association between workplace bullying and psychotropic drug use. Appelberg et al. (Appelberg et al., 1993) reported an association between interpersonal conflicts at work and the use of tranquilizers and hypnotics after adjustment for age, social class and neuroticism, and stratified by marital status in Finnish men. Lavigne and Bourbonnais (Lavigne and Bourbonnais, 2010) reported an association between psychological harassment and psychotropic drug use after adjustment for gender, age, and several other psychosocial work factors among Canadian correctional officers. The study by Richman et al. (Richman et al., 1999) reported an association between generalized workplace abuse and use of prescription drugs (tranquilizers, antidepressants, and sedatives) after adjustment for age, race, and occupation among American male university employees. The study by Traweger et al. (Traweger et al., 2004) showed that being a victim of bullying was associated with the use of antidepressants, benzodiazepines, analgetics, stimulants, and phytotherapeutics in Austria, but this finding was based on a crude association without adjustment. Vartia (Vartia, 2001) reported that bullied employees used both sleep-induced drugs and sedatives more often than the other subjects; observers were also more likely to use them than nonbullied, but the use of these drugs did not correlate with the duration or the frequency of bullying among Finnish municipal employees. However, no information was provided on covariates. In all these studies, the measurement of bullying and/or psychotropic drug use were based on single items. These very few studies also underlined the scarcity of the literature on this topic.

Our results are in agreement with these studies. Furthermore, as never observed before, we found dose-response associations between frequency and duration of bullying and psychotropic drug use. Past exposure to bullying had still an impact on psychotropic drug use, pointing to the long term effects of bullying, even when the exposure had stopped. Being an observer of bullying was a risk factor of psychotropic drug use suggesting that workplaces prone to bullying may have a detrimental effect on employees' health, even if employees are not directly concerned by the phenomenon. Our results are in agreement with the study by Vartia (Vartia, 2001) finding an association between observing bullying and the use of sleep-induced drugs and sedatives. Finally, we found that physical and mental health status may mediate the association between workplace bullying and psychotropic drug use, something never reported before. Our study also stated gender differences as physical and mental health status may play a stronger mediating role among men than among women, suggesting that other factors might mediate the association between bullying and psychotropic drug use among women.

Conclusion

Our findings underline the strong association between workplace bullying and psychotropic drug use. Our study also demonstrates that the association between workplace bullying and psychotropic drug use may be mediated by health-related factors, which is a finding that allows a better understanding of the mechanisms leading to psychotropic drug use. More information from prospective etiological studies would be helpful. More research on management styles and organisational policies would also be useful to provide guidelines to policies oriented towards preventing bullying at the workplace. Better understanding of bullying, its determinants and consequences, as well as increasing efforts toward prevention are urgently needed.

Acknowledgements:

The authors thank Drs JL Battu, C Beyssier, N Blanchet, C Breton, M Bueno-Michel, JF Canonne, G Dalivoust, A Faivre, F Fournier, G Gazazian, G Gibelin-Dol, E Griffaton, T Ibagues, B Jaubert, J Leroy, M Lozé, G Magallon, P Presseq, G Roux, and C Vitrac, as well as Drs J Chiaroni, C Kaltwasser, and M Signouret, for their help in constructing the network of voluntary occupational physicians, and last but not least S Mocaer and P Sotty for their support and interest in this research program. A pre-test of this survey was performed in 2003 thanks to the contribution of Drs AM Boustière, C Breton, C Cervoni, A Faivre, C Gravier, E Halimi, M Isnard, MC Jacquin, M Lafon-Borelli, J Laudicina, D Londi, M Lozé, G Magallon, V Marcelot, M Méric, C Milliet, F Occhipinti, P Occhipinti, H Raulot-Lapointe, and MO Vincensini. The authors' thanks also go to T Theorell for his help in providing the German version of the LIPT questionnaire, and to I Revue and R Revue for their help in translating and back-translating this questionnaire. Finally, the authors thank all the employees who participated to the survey and made this study possible. This study was supported by the DRTEFP PACA of the French Minister of Labour.

References:

- Alonso J , Angermeyer MC , Bernert S , Bruffaerts R , Brugha TS , Bryson H , de GG , Graaf R , Demyttenaere K , Gasquet I , Haro JM , Katz SJ , Kessler RC , Kovess V , Lepine JP , Ormel J , Polidori G , Russo LJ , Vilagut G , Almansa J , rbadzadeh-Bouchez S , Autonell J , Bernal M , Buist-Bouwman MA , Codony M , Domingo-Salvany A , Ferrer M , Joo SS , Martinez-Alonso M , Matschinger H , Mazzi F , Morgan Z , Morosini P , Palacin C , Romera B , Taub N , Vollebergh WA . 2004 ; Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project . *Acta Psychiatr Scand Suppl* . 55 - 64
- Appelberg K , Romanov K , Honkasalo ML , Koskenvuo M . 1993 ; The use of tranquilizers, hypnotics and analgesics among 18,592 Finnish adults: associations with recent interpersonal conflicts at work or with a spouse . *J Clin Epidemiol* . 46 : 1315 - 1322
- Bjorkqvist K , Osterman K , Hjelt-Back M . 1994 ; Aggression among university employees . *Aggressive Behaviour* . 20 : 173 - 184
- Cowie H , Naylor P , Rivers I , Smith P-K , Pereira B . 2002 ; Measuring workplace bullying . *Aggression and Violent Behavior* . 7 : 33 - 51
- Einarsen S . 2000 ; Harassment and bullying at work: a review of the Scandinavian approach . *Aggression and Violent Behavior* . 5 : 379 - 401
- Einarsen S , Raknes BI , Matthiesen SB . 1994 ; Bullying and harassment at work and their relationships to work environment quality: an exploratory study . *European Work and Organizational Psychologist* . 4 : 381 - 401
- Einarsen S , Skogstad A . 1996 ; Bullying at work: epidemiological findings in public and private organizations . *European journal of work and organizational psychology* . 5 : 185 - 201
- Fuhrer R , Rouillon F . 1989 ; La version française de l'échelle CES-D (Center for Epidemiologic Studies - Depression scale). Description et traduction de l'échelle d'autoévaluation . *Psychiatr Psychobiol* . 4 : 163 - 166
- Hoel H , Cooper CL , Faragher B . 2001 ; The experience of bullying in Great Britain: the impact of organizational status . *European journal of work and organizational psychology* . 10 : 443 - 465
- Lavigne E , Bourbonnais R . 2010 ; Psychosocial work environment, interpersonal violence at work and psychotropic drug use among correctional officers . *Int J Law Psychiatry* . 33 : 122 - 129
- Lecadet J , Vidal P , Baris B , Vallier N , Fender P , Allemand H . 2003 ; Médicaments psychotropes : consommation et pratiques de prescription en France métropolitaine. I. Données nationales, 2000 . *Rev Med Ass Maladie* . 34 : 75 - 84
- Leipzig RM , Cumming RG , Tinetti ME . 1999 ; Drugs and falls in older people: a systematic review and meta-analysis. I. Psychotropic drugs . *J Am Geriatr Soc* . 47 : 30 - 39
- Leymann H . Handanleitung für den LIPT-Fragebogen (Leymann Inventory of Psychological Terror). Materialie Nr. 33 . 1996a ; Deutsche Gesellschaft für Verhaltenstherapie eV, Tübingen .
- Leymann H . 1996b ; The content and development of mobbing at work . *European journal of work and organizational psychology* . 2 : 165 - 184
- Lynch JW , Kaplan GA , Cohen RD , Tuomilehto J , Salonen JT . 1996 ; Do cardiovascular risk factors explain the relation between socioeconomic status, risk of all-cause mortality, cardiovascular mortality, and acute myocardial infarction? . *Am J Epidemiol* . 144 : 934 - 942
- Moisan J , Bourbonnais R , Brisson C , Gaudet M , Vézina M , Vinet A , Grégoire JP . 1999 ; Job strain and psychotropic drug use among white-collar workers . *Work & Stress* . 13 : 289 - 298
- Niedhammer I , David S , Degioanni S . 143 médecins du travail . 2006a ; [The French version of the Leymann's questionnaire on workplace bullying: the Leymann Inventory of Psychological Terror (LIPT)] . *Rev Epidemiol Sante Publique* . 54 : 245 - 262
- Niedhammer I , David S , Degioanni S . 143 occupational physicians . 2006b ; Association between workplace bullying and depressive symptoms in the French working population . *J Psychosom Res* . 61 : 251 - 259
- Niedhammer I , David S , Degioanni S . 143 occupational physicians . 2007 ; Economic activities and occupations at high risk for workplace bullying: results from a large-scale cross-sectional survey in the general working population in France . *Int Arch Occup Environ Health* . 80 : 346 - 353
- Niedhammer I , David S , Degioanni S , Drummond A , Philip P . 143 occupational physicians . 2009 ; Workplace bullying and sleep disturbances: findings from a large scale cross-sectional survey in the French working population . *Sleep* . 32 : 1211 - 1219
- Niedhammer I , Lert F , Marne MJ . 1995 ; Psychotropic drug use and shift work among French nurses (1980-1990) . *Psychol Med* . 25 : 329 - 338
- Niedhammer I , Saurel-Cubizolles MJ , Piciotti M , Bonenfant S . 2000 ; How is sex considered in recent epidemiological publications on occupational risks? . *Occup Environ Med* . 57 : 521 - 527
- Pelfrene E , Vlerick P , Moreau M , Mak RP , Kornitzer M , De Backer G . 2004 ; Use of benzodiazepine drugs and perceived job stress in a cohort of working men and women in Belgium. Results from the BELSTRESS-study . *Soc Sci Med* . 59 : 433 - 442
- Richman JA , Rospenda KM , Nawyn SJ , Flaherty JA , Fendrich M , Drum ML , Johnson TP . 1999 ; Sexual harassment and generalized workplace abuse among university employees: prevalence and mental health correlates . *Am J Public Health* . 89 : 358 - 363
- Salin D . 2001 ; Prevalence and forms of bullying among business professionals: a comparison of two different strategies for measuring bullying . *European journal of work and organizational psychology* . 10 : 425 - 441

- Traweger C , Kinzl JF , Traweger-Ravanelli B , Fiala M . 2004 ; Psychosocial factors at the workplace--do they affect substance use? Evidence from the Tyrolean workplace study . *Pharmacoepidemiol Drug Saf* . 13 : 399 - 403
- Vartia M . 1996 ; The sources of bullying: psychological work environment and organizational climate . *European journal of work and organizational psychology* . 5 : 203 - 214
- Vartia ML . 2001 ; Consequences of workplace bullying with respect to the well-being of its targets and the observers of bullying . *Scand J Work Environ Health* . 27 : 63 - 69
- Virtanen M , Honkonen T , Kivimaki M , Ahola K , Vahtera J , Aromaa A , Lonnqvist J . 2007 ; Work stress, mental health and antidepressant medication findings from the Health 2000 Study . *J Affect Disord* . 98 : 189 - 197
- Wadsworth EJ , Moss SC , Simpson SA , Smith AP . 2005 ; Psychotropic medication use and accidents, injuries and cognitive failures . *Hum Psychopharmacol* . 20 : 391 - 400
- Witchel HJ , Hancox JC , Nutt DJ . 2003 ; Psychotropic drugs, cardiac arrhythmia, and sudden death . *J Clin Psychopharmacol* . 23 : 58 - 77

Table 1

Crude associations between exposure to bullying and psychotropic drug use

	Psychotropic drug use			
	Men		Women	
	Use (N)	Use (%)	Use (N)	Use (%)
Exposure to bullying				
No	469	16.56	1184	29.34
Yes	109	39.78	289	59.47
Exposure to bullying				
No exposure	469	16.56	1184	29.34
Past exposure	11	28.95	72	55.81
Current exposure	96	41.38	210	60.17
Frequency of exposure to bullying				
No exposure	469	16.56	1184	29.34
Weekly	49	33.11	124	55.11
Daily or almost daily	60	47.62	165	63.22
Duration of exposure to bullying				
No exposure	469	16.56	1184	29.34
< 2 years	34	36.17	114	55.07
≥ 2 years, but < 5 years	41	36.28	112	62.57
5 years or more	34	50.75	63	63.00
Observer of bullying				
No	325	15.17	860	27.95
Yes	253	26.24	613	42.45
Combination exposure to bullying/observer				
No exposure	300	14.37	800	27.02
Observer	169	22.72	384	35.75
Exposure to bullying	25	46.30	60	51.72
Exposure to bullying and observer	84	38.18	229	61.89

Chi-Square test

All associations significant at p<0.001

Table 2

Crude associations between covariates and psychotropic drug use

	Psychotropic drug use			
	Men		Women	
	Use (N)	Use (%)	Use (N)	Use (%)
Age (years)		***		***
< 30	68	13.10	247	29.23
30–39	174	17.21	373	27.82
40–49	179	20.96	472	35.44
50 or more	155	21.74	376	38.06

Marital status			*		***
Married, cohabiting	370	17.52		855	29.95
Single, separated, divorced, widowed	208	20.95		614	36.99
Presence of children			NS		**
Yes	303	18.21		765	30.91
No	274	19.07		701	34.58
Education			*		*
Primary, lower vocational, lower secondary	260	19.27		545	34.69
Upper secondary	101	22.10		351	33.82
University	215	16.67		574	30.18
Occupation			**		NS
Blue collar worker	127	16.34		52	29.21
Clerks, service workers	133	23.25		793	32.92
Associate professionals	207	18.84		520	33.31
Managers, professionals	110	17.03		100	28.90
Working hours a week			NS		NS
<40	330	19.20		1164	31.92
≥40	222	17.93		265	35.15
Night work			**		*
No	499	18.02		1362	32.24
Yes	75	24.19		100	38.02
Number of physico-chemical exposures			NS		***
0	285	17.25		951	31.23
1	85	19.36		297	33.87
2	69	21.63		114	32.76
≥ 3	139	19.97		111	44.22
Self-reported health			***		***
Good	404	14.65		1040	26.73
Poor	172	50.29		428	69.26
Depressive symptoms			***		***
No	237	10.50		838	24.12
Yes	324	42.52		602	64.59
Chi-Square test					
*					
p<0.05					
**					
p<0.01					

p<0.001					

Table 3

Exposure to bullying and psychotropic drug use according to logistic regression analysis

	Psychotropic drug use			
	Men		Women	
	OR	95% CI	OR	95% CI
Exposure to bullying				
No	1		1	
Yes	3.10	2.36–4.08	3.49	2.86–4.28
Exposure to bullying				
No exposure	1		1	
Past exposure	2.28	1.10–4.71	3.09	2.14–4.47
Current exposure	3.22	2.40–4.32	3.56	2.82–4.51
Frequency of exposure to bullying				
No exposure	1		1	
Weekly	2.30	1.58–3.33	2.96	2.23–3.92
Daily or almost daily	4.36	2.97–6.40	4.06	3.10–5.33
Duration of exposure to bullying				
No exposure	1		1	
< 2 y	2.95	1.87–4.64	3.03	2.26–4.06
≥ 2 y, but < 5 y	2.65	1.75–4.00	3.94	2.85–5.44
5 years or more	4.25	2.55–7.09	3.84	2.50–5.89
Observer of bullying				
No	1		1	
Yes	1.92	1.58–2.34	1.92	1.68–2.21
Combination exposure to bullying/observer				
No exposure	1		1	
Observer	1.71	1.37–2.13	1.55	1.33–1.81
Exposure to bullying	4.84	2.70–8.66	3.12	2.12–4.61
Exposure to bullying and observer	3.45	2.52–4.71	4.32	3.41–5.46

OR: odds ratio CI: confidence interval

OR adjusted for age, marital status, presence of children, education, occupation, working hours a week, night work, and physico-chemical exposures

Bold OR: significant at 5%

All bullying variables were significant at p<0.001

Table 4

Factors associated with psychotropic drug use according to logistic regression analysis

	Psychotropic drug use			
	Men (N=2911)		Women (N=4322)	
	OR	95% CI	OR	95% CI
Exposure to bullying	***		***	
No	1		1	
Yes	3.10	2.36–4.08	3.49	2.86–4.28
Age (years)	***		***	
< 30	1		1	
30–39	1.56	1.12–2.17	1.01	0.81–1.25
40–49	2.06	1.46–2.90	1.44	1.15–1.78
50 or more	2.32	1.64–3.29	1.53	1.23–1.90
Marital status	**		***	
Married, cohabiting	1		1	
Single, separated, divorced, widowed	1.40	1.09–1.78	1.31	1.14–1.51
Presence of children				
Yes	1		1	
No	1.01	0.80–1.28	1.09	0.93–1.27
Education				
Primary, lower vocational, lower secondary	1.17	0.89–1.54	1.22	1.01–1.48
Upper secondary	1.30	0.96–1.77	1.19	0.99–1.43
University	1		1	
Occupation	*			
Blue collar worker	0.61	0.41–0.92	0.78	0.49–1.24
Clerks, service workers	1.01	0.70–1.46	1.06	0.78–1.42
Associate professionals	0.82	0.60–1.11	1.18	0.89–1.56
Managers, professionals	1		1	
Working hours a week				
<40	1		1	
≥40	0.94	0.77–1.16	1.08	0.90–1.29
Night work	*			
No	1		1	
Yes	1.35	1.00–1.83	1.21	0.92–1.60
Number of physico-chemical exposures			*	
0	1		1	
1	1.20	0.90–1.59	1.06	0.89–1.25
2	1.49	1.07–2.06	0.98	0.76–1.26
≥ 3	1.27	0.97–1.67	1.56	1.18–2.08

OR: odds ratio CI: confidence interval

* p<0.05

** p<0.01

*** p<0.001

Bold OR: significant at 5%

Table 5
Exposure to bullying and psychotropic drug use according to logistic regression analysis including additional adjustment for self-reported health and depressive symptoms

	Psychotropic drug use			
	Men		Women	
	OR	95% CI	OR	95% CI
Exposure to bullying			***	
No	1		1	
Yes	1.31	0.95–1.80	1.78	1.41–2.24
Exposure to bullying			***	
No exposure	1		1	
Past exposure	1.39	0.62–3.12	2.16	1.44–3.23
Current exposure	1.29	0.92–1.81	1.60	1.23–2.10
Frequency of exposure to bullying			***	
No exposure	1		1	
Weekly	1.11	0.73–1.68	1.56	1.13–2.14
Daily or almost daily	1.59	1.03–2.45	2.00	1.48–2.72
Duration of exposure to bullying			***	
No exposure	1		1	
< 2 y	1.14	0.69–1.89	1.55	1.12–2.15
≥ 2 y, but < 5 y	1.12	0.70–1.78	1.86	1.30–2.68
5 years or more	2.02	1.14–3.60	2.22	1.37–3.60
Observer of bullying	*		***	
No	1		1	
Yes	1.28	1.03–1.60	1.32	1.13–1.54
Combination exposure to bullying/observer			***	
No exposure	1		1	
Observer	1.29	1.02–1.65	1.23	1.04–1.46
Exposure to bullying	1.65	0.87–3.13	1.82	1.19–2.79
Exposure to bullying and observer	1.40	0.98–2.02	1.95	1.49–2.55

OR: odds ratio CI: confidence interval

OR adjusted for age, marital status, presence of children, education, occupation, working hours a week, night work, physico-chemical exposures, self-reported health, and depressive symptoms

* : p<0.05

** : p<0.01

*** p<0.001

Bold OR: significant at 5%